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Purpose:  To evaluate the incidence of bisphosphonate related osteonecrosis of the jaw 
following a single dose of zoledronic acid for the treatment of osteoporosis in frail, elderly, 
institutionalized females. 
Materials and Methods: Utilizing a longitudinal prospective study design, data was 
collected from one hundred eighty subjects who were randomly assigned to receive a single 
intravenous infusion of either zoledronic acid (5mg) or placebo.  Dental evaluations were 
completed at baseline (Day 0) and at months 12 and 24.  All patients received daily supplemental 
calcium and vitamin D throughout the course of the trial.   Patients completed a questionnaire to 
provide information regarding their oral hygiene practices to ascertain information that may be 
helpful in detecting risk factors for development of BRONJ.   
Results: Zero cases of osteonecrosis were detected at any time point in the 180 subjects 
who completed the 24-month follow up period. Subject’s race, age, smoking status, oral hygiene 
practices, frequency of dental visits and use of a removable dental prosthesis did not contribute 
to the development of BRONJ. 
Conclusion: The administration of a single dose of 5mg of zoledronic acid for the 
treatment of osteoporosis in frail, elderly, institutionalized women does not cause 
bisphosphonate related osteonecrosis of the jaw.  
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1.0  INTRODUCTION 
According to the 2010 U.S. Census Report, persons 65 years of age or older currently account 
for 12.9% of the total population within the United States.  By the year 2030, that percentage is 
expected to climb to 19%, representing a total of 72 million Americans, more than double the 
number reported in the 2000 Census. This rapid shift in the age of the population will present 
major challenges to our healthcare system as the number of individuals who suffer age-related 
illnesses increases (Aging, 2013).    
Osteoporosis is an example of a disease that disproportionally affects older members of 
society. If untreated, osteoporosis is associated with high rates of morbidity, can significantly 
affect the quality of life and dramatically increases the risk of secondary life-threatening 
complications (WHO, 2004).   Treatment for osteoporosis varies widely depending on the level 
of bone mass deficiency. Pharmacological intervention is often employed to treat advanced cases 
of the disease.  The class of drugs that are typically utilized for osteoporosis therapy are known 
as bisphosphonates.  Bisphosphonates interfere with osteoclast function and effectively reduce 
bone turnover.  Bisphosphonates are prescribed in an oral form or through intravenous infusion.  
The oral form of the drug requires a strict daily or weekly drug regimen that must be preceded by 
a period of fasting and requires patients to ingest the tablet with a full glass of water to avoid 
esophageal irritation and remain upright for 30-60 minutes to maximize absorption (Rakel et al., 
2011).  Intravenous bisphosphonate therapy for the treatment of osteoporosis requires only 
yearly infusions making it a more practical and effective alternative for some elderly patients 
who may have difficulty complying with the dosing protocol required with the oral form.  
Unfortunately, the long-term use of intravenous bisphosphonates has been associated with the 
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undesirable side effect known as bisphosphonate related osteonecrosis of the jaw (BRONJ).  The 
purpose of this study was to evaluate the incidence of BRONJ following a single dose of 5mg of 
zoledronic acid administered to elderly, institutionalized, post-menopausal women who suffer 
from osteoporosis. The results of this study could possibly contribute to the creation of a 
universal protocol for the treatment of osteoporosis in women who are admitted to nursing 
homes or assisted living communities. 
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2.0  REVIEW OF LITERATURE 
2.1 DEFINITION AND PREVALENCE OF OSTEOPOROSIS 
Osteoporosis is a bone disease characterized by a decrease in bone mass and increased risk of 
bone fracture.  In 1997, the World Health Organization developed a working definition of 
osteoporosis based on the qualitative assessment of bone mineral density (BMD) using dual 
energy X-ray absorptiometry (DXA).  The WHO concluded that a BMD that lies 2.5 standard 
deviations or more below the average value for young healthy women is considered diagnostic 
for the disease (Kanis et al., 2008).  Projections based on this definition have concluded that as 
many as 12 million Americans over the age of 50 are living with osteoporosis and another 40 
million are at risk with low bone mass.  By 2020, those figures are estimated to jump to 14 
million cases of active osteoporosis and 47 million cases of low bone mass (National, 2002).  
This dramatic increase in prevalence is the direct result of a shift in population demographic 
toward an aging senior population and an overall increase in the average life expectancy (Becker 
et al., 2010). As the number of new cases of osteoporosis and the corresponding increase in the 
number of disease-related morbidities continues to rise, management of osteoporosis will 
become a major challenge within the healthcare community. 
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2.2 CONSEQUENCES OF UNTREATED OSTEOPOROSIS 
Individuals diagnosed with osteoporosis are at a heightened risk of suffering a debilitating bone 
fracture due to the deterioration of bone structure. Women, who are disproportionately affected 
compared to men, represent 80% of cases and have a 40-50% lifetime risk of experiencing an 
osteoporosis-related fracture (Department 2004, Johnell et al. 2005). The short and long-term 
consequences of a bone disease-related fracture can be devastating to a patient’s health and can 
ultimately lead to permanent morbidity and even fatality.  In 1990, the number of deaths 
worldwide that were associated with hip fractures was 740,000 (Johnell et al., 2004).  In 1993, a 
Department of Commerce Report found that 300,000 hip fractures occurred in the United States 
every year and that an average of 24% (72,000) of individuals 50 years or older who experienced 
a hip fracture, died within one year (US, 1993). Those patients who do survive may continue to 
suffer from permanent disabilities, with as many as 7% of patients having ‘some degree’ of 
permanent disability and 8% requiring ‘long-term institutional care' (Harvey et al., 2010, Leibson 
et al., 2002).  Studies evaluating patients following an osteoporosis-related fracture have also 
reported a reduced ‘health-related quality of life’ (Boonen et al., 2008). 
In 2004, the Surgeon General’s report titled “Bone Health and Osteoporosis” described 
the serious impact the increased prevalence of osteoporosis could have on the overall health of 
the American population, as well as the financial burden it could exact on our entire health care 
system (Department, 2004). With an estimated 1.5 million fractures occurring each year as the 
result of osteoporosis, the direct cost of treating bone disease-related fractures is upwards of $17 
billion annually and is expected to reach $25 billion by 2025 (Riggs et al., 1995, Burge et al., 
2007).  
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2.3 MANAGEMENT OF OSTEOPOROSIS 
If detected early, osteoporosis can often be managed effectively by simple modification of a 
patient’s daily intake of calcium and vitamin D, as well as, by increasing an individual’s level of 
physical activity.  For patients who present with advanced stages of bone deterioration, more 
aggressive therapies involving administration of antiresorptive pharmaceuticals are often utilized 
(Department, 2004). Drug therapy for treatment of osteoporosis most commonly involves 
administration of a class of drugs known as bisphosphonates to help improve bone mineral 
density by decreasing bone turnover.  Bisphosphonates are complex antiresorptive agents that act 
on specific biochemical and cellular pathways and inhibit osteoclast-mediated bone resorption 
without interfering with bone formation (Deal, 2009).    
2.4 BISPHOSOPHNATES 
The chemical structure of bisphosphonates is based on a derivative of inorganic pyrophosphate, a 
natural ring compound made up of two phosphate rings linked by an ester bond.  Newer 
bisphosphonates incorporate a nitrogen or amino group that amplifies the potency of the drug’s 
antiresorptive properties by 10-10,000 compared to the earlier non-nitrogen containing 
bisphosphonates (Drake et al., 2008).   These newer aminobisphosphonates act by inhibiting 
farnesyl diphosphonate synthase, a critical component of cholesterol synthesis.  Interference of 
this pathway results in disruption of the cell’s ability to carry out intracellular transport, organize 
an intracellular scaffold and undergo cellular proliferation, ultimately disabling normal osteoclast 
function (Woo et al., 2006).  
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2.5 COMPLIANCE OF ORAL BISPHOSPHONATES 
Bisphosphonates available for the treatment of osteoporosis can be administered in two main 
forms: a tablet or oral solution, which is absorbed following enteral drug administration, or a 
fluid solution, administered through an intravenous infusion. With over 190 million prescriptions 
dispensed worldwide, the oral form of bisphosphonates has been the most commonly employed 
treatment strategy for patients suffering from osteoporosis; however, the strict intake 
requirements, which involve a daily or weekly drug regimen and close supervision by a nurse for 
30-60 minutes following ingestion, make it difficult for elderly patients to adhere to the rigorous 
dosing protocol (Advisory, 2007, Watts et al., 2010). An investigation examining the compliance 
of oral bisphosphonate therapy in post-menopausal women found that in patients over the age of 
65, as few as 28% of individuals taking a daily oral bisphosphonate and 35% taking a weekly 
oral bisphosphonate continued treatment at the end of one year. Lack of stringent compliance to 
the oral therapy has significant influence on the effectiveness of treatment and has been shown to 
increase the risk of osteoporosis related fracture by up to 16% (Cramer et al., 2005). In an effort 
to avoid complications resulting from poor compliance with use of oral bisphosphonates, 
therapies utilizing once yearly intravenous bisphosphonate administration have been employed to 
treat cases of advanced osteoporosis.   
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2.6 ZOLEDRONIC ACID 
In August 2007, the United States Food and Drug Administration approved the administration of 
zoledronic acid (Reclast©) once per year for the treatment of patients diagnosed with 
osteoporosis (Reclast, 2013).    Unlike oral bisphosphonates that have a relative low 
bioavailability of less than 5%, greater than 60% of intravenously administered bisphosphonates 
is available for deposition within the bone matrix, thereby reducing the need for frequent 
administration (Gutta et al., 2007, Hamdy et al., 2010). The increased potency and long duration 
of activity, up to 12 months, has led to concern regarding the safety profile of IV 
bisphosphonates, particularly findings that have shown a positive correlation of long term IV 
bisphosphonate use with the development of osteonecrosis of the jaw (Reid et al., 2002, Dodson 
et al., 2009).  
2.7 DEFINITION AND CHARACTERISTICS OF BRONJ 
In 2007, the American Association of Oral and Maxillofacial Surgeons released a position paper 
that defined bisphosphonate-related osteonecrosis of the jaw as an exposed area of bone in the 
maxillofacial region that persists for greater than eight weeks, in a patient without any history of 
radiation therapy to the head or neck (Advisory, 2007). While the exact etiology behind BRONJ 
remains unclear, one of the predominate theories is that a decrease in osteoclast activity leads to 
a dramatic reduction in bone turnover, making the bone more susceptible to structural 
microdamage.  In cases where bone becomes exposed through trauma or surgical therapy, the 
cumulative effects of bone microdamage, combined with the introduction of high quantities of 
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bacteria from within the oral environment, can result in a delay of healing and an inability of the 
tissues to initiate normal reparative processes (Siddiqi et. al., 2009).   
The clinical presentation of BRONJ is characterized by localized bone sequestration and 
is associated with high levels of pain, soft tissue swelling, infection, and in some cases, 
loosening of teeth or draining fistula (Ficarra et al., 2007).  During the early stages of 
development, signs of BRONJ may not be evident upon radiographic analysis.  As the condition 
develops, areas of affected bone may appear mottled in nature and have a radiographic 
presentation similar to classic periapical pathology or inflammatory conditions such as 
osteomyelitis (Ficarra et al., 2007).  Microscopic evaluation of histologic samples collected from 
areas of bone necrosis in patients suffering from BRONJ consistently show non-viable bone 
trabeculae with empty lacunae and chronic inflammatory cell infiltrate composed primarily of 
neutrophils, histiocytes, eosinophils and plasma cells.  Although a wide variety of pathogenic 
bacterial species are routinely collected from sites of BRONJ, samples frequently show 
disproportionally high levels of infiltrating actinomyces species (Almazrooa et al., 2009, 
Dannemann et al., 2007, Ficarra et al., 2007).   
2.8 RISK FACTORS ASSOCIATED WITH BRONJ 
The central focus of a number of recent studies has been to outline the risk factors associated 
with the development of BRONJ.  Differences in the cumulative dosage of the bisphosphonate 
administered, the duration of therapy, and the route of administration can significantly alter a 
patient’s overall risk for osteonecrosis.  Bisphosphonate therapy employed for the treatment of 
malignant diseases such as multiple myeloma or breast cancer typically places patients at an 
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increased risk of developing BRONJ because treatment requires a higher dosage, more frequent 
administration, and the use of the more potent intravenous forms of the drug (Statz et al., 2007).    
The uneven distribution of cases of osteonecrosis among the various bisphosphonates has 
also been well documented.  The IV bisphosphonates pamidronic acid (Aredia©) and zoledronic 
acid (Reclast©), two of the newer aminobisphosphonates, have been shown to increase the risk of 
BRONJ, compared to oral forms of the drug such as alendronic acid (Alendronate©) and 
risedronic acid (Actonel©) (Mavrokokki 2007 et al., Abu-Id et al., 2008).   A hospital-based case-
control study completed by Wessel et al. in 2008, evaluated the association between 
osteonecrosis and potential risk factors.  The authors found a 30-fold increase in risk of 
osteonecrosis in patients treated with zoledronic acid and a statistically significant association 
between smoking and BRONJ.  
Other factors such as patient’s anatomic features, social behavior (i.e. smoking), 
population demographic, and certain systemic or genetic factors, have also been found to 
contribute to the development of BRONJ  (Walter et al., 2008, Otto et al., 2011, Hess et al., 
2008, Advisory, 2007, Katz et al., 2011, Dodson et al., 2009, Cartsos et al., 2010 , Abu-Id et al., 
2008).  A history of substandard dental health may also place a patient at an increased risk for 
BRONJ. Underlying dental health conditions or the completion of surgical dental procedures 
such as dental extractions, placement of dental implants, active periodontal disease, improperly 
fitting dentures, and areas of bony exostosis, can precipitate the onset of osteonecrosis. (Hoff et 
al., 2008).   In a 2008 literature review, Rizzoli et al. found that the majority of cases of BRONJ 
occurred following tooth extraction and that the development of BRONJ was more concentrated 
in patients being treated for additional diseases (Rizzoli et al., 2008).   
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2.9 INCIDENCE OF BRONJ  
The cumulative risk of developing BRONJ is estimated to range from 0.8 to 12% in patient 
populations who have a history of IV bisphosphonate use (Advisory, 2009).   Reports estimating 
the incidence of BRONJ associated with oral bisphosphonates have found the range closer to 1 in 
10,000 and <1 in 100,000 patient-treatment years.  A 2008 comprehensive literature review 
analyzing the risk of BRONJ in patients with osteoporosis estimated an incidence rate of 1 event 
per 20,000-110,000 patient-years (Rizzoli et al., 2008).  Similarly, the results of a large multi-
center study evaluating the risk of osteonecrosis among patients being treated for osteopenia with 
yearly infusions of 5mg of zoledronic acid revealed only a single case of BRONJ among 5,903 
patients treated over the course of 36 months (Grbic et al., 2010).   
While studies specifically designed to evaluate the incidence of BRONJ in patients being 
treated for osteoporosis have found a lower incidence of BRONJ compared to populations being 
treated with IV bisphosphonates for malignant disease, the risk of developing BRONJ is still 
significantly higher than patients being treated with oral bisphosphonates.  A 2010 medical 
claims study that evaluated the risk of adverse jaw outcomes in patients with a history of 
bisphosphonate use found that patients who were treated with IV bisphosphonates for 
osteoporosis had a fourfold increase risk of having a claim for ONJ compared to patients who 
had received the oral form (Cartsos et al., 2010).   
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3.0  METHODOLOGY 
This study was a randomized, double blind, placebo-controlled clinical trial examining 
the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in institutionalized, 
frail, elderly women suffering from osteoporosis. In order to meet eligibility requirements, 
participants were required to be 65 years or older, post-menopausal women, residing in an 
assisted living or nursing home facility, and having a DXA score (T-score -2.5 at the total hip, 
femoral neck or spine) or low bone mass (T-score < -2.0 at the total hip, femoral neck or spine) 
that met the WHO established criteria for osteoporosis. Exclusion criteria for this study were 
children, men, any patients with signs of subacute illness, patients with allergies or 
contraindications to bisphosphonate therapy, patients with creatinine clearance of less than 
<30ml/mm, and patients unable to bear weight or assist with transfer to the chair.  The screening 
process was based on a detailed medical history, physical exam, dental exam, chart review, and 
baseline laboratory analyses, including BUN/creatinine, liver function tests, TSH, calcium, PTH, 
25-hydroxyvitamin D, and alkaline phosphatase level.  The only restriction for concomitant or 
previous medication use was a history of bisphosphonate use for greater than one year in the 
previous two years prior to enrollment. 
Utilizing a longitudinal prospective study design, data was collected from one hundred 
eighty subjects (n=180) randomly assigned to receive a single intravenous infusion of either 
zolendronic acid (5mg) or placebo at baseline (Day 0).  Subjects were monitored with 
institutional evaluations at screening, randomization, Day 1, Day 2, Month 6, Month 12, and 
Month 24, to assess clinical parameters related to the status of the subjects’ bone mineral density 
and overall systemic condition. All participants received daily supplemental calcium and vitamin 
D throughout the course of the trial. During the screening process and at months 12 and 24, 
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dental assessments were conducted to evaluate the intra-oral quality of health of the teeth and 
soft tissues and to assess the status of the subject’s dental hygiene.  During these dental 
assessments, subjects were carefully evaluated for the presence of any acute infections, evidence 
of pathology, or signs suggestive of bisphosphonate-related osteonecrosis of the jaw.   A 
questionnaire was also administered to each patient during evaluations to collect data on oral 
hygiene practices and ascertain information helpful in detecting risk factors for development of 
BRONJ.  All screening and evaluation visits were conducted at the subjects’ care facility. 
 Participants who met eligibility requirements were randomized in a 1:1 ratio to either 5 
mg intravenous zoledronic acid or placebo given in a single dose.  The placebo or study drug was 
prepared by the UPMC Investigational Drug Service (IDS) and was administered by means of an 
intravenous catheter. 
 A comprehensive description outlining the potential risks and benefits was provided to 
the participants and was reviewed prior to matriculation into the study.  Those individuals who 
agreed to participate in the study signed a detailed informed consent agreement reviewing the 
purpose, nature of the study and the potential risks and benefits of the treatment. 
 The primary endpoints of the study were the development of BRONJ based on the 2007 
definition provided by the American Association of Oral and Maxillofacial Surgeons, or the 
completion of the 24-month evaluation period without any development of bisphosphonate 
related osteonecrosis of the jaw. 
 Simple descriptive statistics were employed to compute participant demographic data and 
information collected from the dental surveys to help formulate relevant trends within the study 
population and assess the total number of cases of BRONJ.  
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4.0  RESULTS 
The results of the trial are based upon all the data collected from the 180 randomized 
subjects at baseline, as well as the 12 and 24 month dental evaluations.   Data collection began in 
December 2007 and was completed in February 2014.  Patient information was collected from 
eleven institutions located within a 30-mile radius of the City of Pittsburgh, Pennsylvania.  All 
subjects resided in a nursing home or assisted or independent living community.  
Zero cases of BRONJ were detected in the study population, including subjects receiving 
bisphosphonates and placebo, at any time point within the study. Variations in participants’ oral 
hygiene practices, social behaviors, population demographics and systemic health status had no 
influence on the development of adverse oral disease outcomes. During the clinical trial, dental 
screenings were completed at baseline on 59 subjects who chose not to enter the study, did not 
meet eligibility criteria, or were lost to follow up.  Data presented within the results reflects only 
the information collected from the 180 subjects who completed the 24 month follow-up period. 
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4.1 STATISTICAL ANALYSIS 
Analysis of the data collected revealed that 176 (97.8%) of the participants were greater than 75 
years old, with the remaining 4 (2.2%) subjects ranging in age from 65-75 years (Table 1). The 
majority of subjects described themselves as Caucasian (97.8%), with 6 (3.3%) participants 
identifying their race as African American (Table 1).  Among the 180 participants, 48 (25.7%) 
reported a previous history of tobacco use, while 6 (3.3%) subjects reported current tobacco use 
and 126 reporting no history of tobacco use (70%) (Table 1).  
 
TABLE 1 
Population Age, Race and Smoking Status 
Age 55-65 65-75 >75 
# Subjects 0/180 4/180 176/180 
Percentage 0% 2.2% 97.8% 
 
Race Black White Other 
# Subjects 6/180 174/180 0/180 
Percentage 3.3% 96.7% 0% 
 
Smoking Status Current Former No History 
# Subjects 6/180 48/180 126/180 
Percentage 3.3% 26.7% 70.0% 
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The structure of the study was purposefully designed to allow a realistic assessment of the oral 
hygiene behavior and professional dental practices within an elderly patient population.   Eighty-
nine subjects (49.4%) reported only seeking dental care in the case of an emergency, while 31 
(17.2%) subjects reported visiting their dentist once per year, and 60 (33.3%) subjects reported 
routine care at six month intervals (Table 2).   All participants in the study were asked to 
describe the condition of their dental health as good, fair, or poor.  One-hundred subjects 
(55.6%) reported their dental health as good, while 67 (37.2%) described their dental health as 
fair, and 13 subjects (7.2%) reported the condition of their dental health as poor (Table 2).   
 
TABLE 2 
Population Frequency of Dental Visits Per Year, Subject Dental Hygiene Assessment  
Dental Visits/Year Emergency Only 1/Year 2/Year 
# Subjects 89/180 31/180 60/180 
Percentage 49.4% 17.2% 33.3% 
 
Dental Health Assessment Poor Fair Good 
# Subjects 13/180 67/180 100/180 
Percentage 7.2% 37.2% 55.6% 
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An important component of the study was to evaluate the oral hygiene practices of 
individual subjects to assess the dental health of the study population and investigate trends that 
may be helpful in predicting cases of BRONJ.  Each subject was asked to indicate the number of 
times per day they brushed their teeth, flossed their teeth, and used any mouth-rinsing agent 
(Table 3).  Participant responses range from zero times per day to three times per day for each 
question.  Analysis of the data revealed that most subjects within the study routinely brush their 
teeth twice per day and do not use mouth rinse or floss their teeth. 
 
TABLE 3 
Population Hygiene Practices – Times Brush/Day, Times Floss/Day, Times Rinse/Day 
 
Times Brush/Day     0/Day 1/Day 2/Day 3/Day 
# Subjects 4/180 47/180 61/180 16/180 
Percentage 2.2% 26.1% 33.9% 8.9% 
 
Times Floss/Day     0/Day 1/Day 2/Day 3/Day 
# Subjects 91/180 25/180 7/180 5/180 
Percentage 50.1% 13.9% 3.9% 2.8% 
 
Times Mouthrinse/Day 0/Day 1/Day 2/Day 3/Day 
# Subjects 107/180 61/180 11/180 1/180 
Percentage 59.4% 33.9% 6.1% 0.1% 
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Of the 180 participants, seventy-three subjects reported routinely wearing a removable 
prosthesis: 50 (27.8%) subjects presented with a complete maxillary and mandibular denture and 
the remaining 23 (12.8%) subjects wore a single arch complete denture or a removable partial 
denture (Table 4). 
TABLE 4 
Population Use of a Removable Prosthesis 
Removable Prosthesis  Complete Dentures Removable Prosthesis 
(Single Arch CD, RPD(s)) 
# Subjects 50/180 23/180 
Percentage 27.8% 12.8% 
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5.0  DISCUSSION 
The majority of cases of BRONJ occur in patient populations that require frequent 
administration of intravenous bisphosphonates for the treatment of malignant disease.  The 
purpose of this study was to evaluate the incidence of BRONJ following a single infusion of 
zoledronic acid.  Irrespective of subjects’ hygiene practices, age, race, history of tobacco use, or 
utilization of a removable dental prosthesis, no subjects within the study presented with any 
symptoms suggestive of BRONJ through the 24-month follow-up period.  These results indicate 
that a single dose of 5mg zoledronic acid administered intravenously for the treatment of 
osteoporosis does not appear to be associated with the development of bisphosphonate-related 
osteonecrosis of the jaw in postmenopausal women.  
In 2007, a large multi-center study titled ‘The Health Outcomes and Reduced Incidence 
with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial’ investigated the clinical 
benefit of utilizing intravenous bisphosphonate therapy to treat cases of advanced osteoporosis. 
A total of 7,765 patients were recruited for the study and 3,876 subjects received 1-3 doses of 
5mg zoledronic acid over the course of 36 months.  The authors concluded that a “once-yearly 
infusion of zoledronic acid significantly reduced the risk of vertebral, hip and other fractures” 
(Black et al., 2007).   Similar findings were reported in a comprehensive literature review 
published by Woodis in 2008 in The Annals of Pharmacology.  The review analyzed the results 
of five randomized controlled studies and concluded that yearly zoledronic acid administration 
decreased burn turnover markers, reduced the vertebral fracture rate by approximately 70%, and 
significantly increased bone mineral density in the hip, femur, and spine (Woodis et al., 2008).    
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In 2008, Rizzoli et al. completed a literature review analyzing the risk of developing 
BRONJ in patients being treated for osteoporosis.  The review included studies utilizing oral as 
well as intravenous forms of bisphosphonates. The authors concluded that the risk of 
osteonecrosis is low and estimated an incidence rate of 1 event per 20,000-110,000 patient-years 
(Rizzoli et al., 2008). These findings were reinforced by a study published in 2010 by Grbic et 
al., which evaluated the incidence of osteonecrosis among 5,903 patients enrolled within the 
HORIZON Study.   The results indicated that among the 5,903 patients who received zoledronic 
acid, only a single case of osteonecrosis was documented.  The authors concluded that the 
incidence of BRONJ was less than one in 14,200 patient treatment-years and that the risk of 
osteonecrosis is rare among patients being treated for osteopenia with yearly infusions of 5mg of 
zoledronic acid (Grbic et al., 2010). The results obtained within our clinical trial correlate closely 
with the findings of previously completed studies.  The overall risk of developing BRONJ in a 
population being treated for osteoporosis appears to be very low. 
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6.0  CONCLUSION 
We conclude from our study of 180 frail, elderly, institutionalized women, that a single dose of 
5mg zoledronic acid for the treatment of osteoporosis does not cause bisphosphonate related 
osteonecrosis of the jaw.  Recommendations for future clinical trials include incorporating a 
larger sample size and extending the follow-up period. 
 
 21 
BIBLIOGRAPHY 
Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al: “Bis-phossy jaws” e  
high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J  
Craniomaxillofac Surg 36: 95e103, 2008 
 
"Aging Statistics." Department of Health and Human Services. N.p., n.d. Web. 05 September  
2013. 
 
Almazrooa, SA., Woo, SB. Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis  
of the Jaw: A Review. JADA 2009;140;864-875. 
 
Advisory Task Force on Bisphophonate-Related Osteonecrosis of the Jaws, American  
Association of Oral and Maxillofacial Surgeons. American Association of Oral and 
Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the 
jaws. J Oral Maxillofac Surg. 2007;65:369–376. 
 
Becker, DJ, Kilgore, ML, Morrisey, MA. The Societal Burden of Osteoporosis. Current  
Reheumatology Report. 2010 Jun; 12 (3): 186-91. 
 
Black DM, Delmas PD, Eastell R, for the HORIZON Pivotal Fracture Trial Group. Once-yearly  
zoledronic acid 5 mg for treatment of post- menopausal osteoporosis. N Engl J Med. 
2007;356:1809-1822.  
 
Boonen, S, Singer, AJ. Osteoporosis Management: Impact of Fracture Type on Cost and Quality 
of Life in Patients At Risk for Fracture I. Current Medical Research and Opinion. 2008 
Jun;24(6):1781-8. 
 
Burge R, Dawson-Hughes B, Solomon DH, et al.: Incidence and economic burden of 
osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007, 
22:465–475.  
Cartsos VM, Zhu S, Zavras AI: Bisphosphonate use and the risk of adverse jaw outcomes: A  
medical claims study of 714,217 people. J Am Dent Assoc 139:23, 2008  
 
Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with 
bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr 
Med Res Opin 2005;21: 1453-60. 
Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecro- sis related to  
bisphosphonate therapy: a severe secondary disorder. Bone. 2007;40(4):828-834.  
 
Deal, C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5:20–27. 
 22 
 
Department of Health and Human Services. Bone health and osteoporosis: a report of the 
Surgeon General. Rockville, MD: Department of Health and Human Services, Office of 
the Surgeon General, 2004. 
Dodson, TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of 
the jaws. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):44-52. 
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action in clinical practise.  
Mayo Clin Proc 2008;83(9):1032–45.  
 
Ficarra, G, Beninati, F. Bisphosphonate-related Osteonecrosis of the Jaws: An Update on  
Clinical, Pathological and Management Aspects. Head and Neck Path. 2007 1:132-140. 
 
Grbic JT, Landesberg R, Lin S-Q, et al. Incidence of osteonecrosis of the jaw in women with  
postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With 
Zoledronic Acid Once Yearly Pivotal Fracture Trial. JADA 2008;139(1):32-40. 
 
Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral 
Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: 186–93. 
Hamdy, RC. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low 
bone mass. Drug Des Devel Ther. 2010 Nov 18;4:321-35. 
Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev  
Rheumatol. 2010;6(2):99–105. 
 
Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of  
the jaw among bisphosphonate users. Am J Med 2008;121:475-83, e3.  
 
Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al: Frequency and risk  
factors associated with osteonecrosis of the jaw in cancer patients treated with 
intravenous bisphosphonates. J Bone Miner Res 23: 826e836, 2008. 
 
Johnell O, Kanis J. An estimate of the worldwide prevalence, mortality and disability  
associated with hip fracture. Osteoporos Int 2004;15:897-902. 
 
Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-
7. 
Kanis JA, on behalf of the World Health Organization Scientific Group 2007. Assessment of 
osteoporosis at the primary health-care level. Technical Report. World Health 
Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, 
UK, 2008. 
 
Katz, J, Gong, Y, Salmasinia, D, Hou, W, Burkley, B, Ferreira, P, Casanova, O, Y, T, Langaee, 
J, Moreb, S. Genetic polymorphisms and other risk factors associated with 
 23 
bisphosphonate induced osteonecrosis of the jaw. Int. J. Maxillofac. Surg. 2011; 40: 605-
611. 
Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing 
home use for persons with and without hip fracture: A population-based study. J Am 
Geriatr Soc. 2002 Oct; 50(10): 1644-50. 
Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate- 
associated osteonecrosis of the jaws in australia. J Oral Maxillofac Surg 2007; 65:415–
423 . 
 
National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and low 
bone mass in our nation. Washington (DC): National Osteoporosis Foundation; 2002.  
Otto S, et al., Bisphosphonate-related osteonecrosis of the jaws: Characteristics, risk factors,  
clinical features, localization and impact on oncological treatment, Journal of Cranio-
Maxillo-Facial Surgery (2011), doi:10.1016/j.jcms.2011.05.003 
 
Rakel, A, Boucher, A, Ste-Marie, L. Role of Zoledronic Acid in the Prevention and Treatment of 
Osteoporosis.  Clinical Interventions in Aging. 2011: 6 89-99. 
 
"Reclast (Zoledronic Acid) Approval Package." U.S. Food and Drug Administration. N.p., n.d.  
Web. 12 September 2014. 
 
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, 
Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, 
Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, 
Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous 
zoledronic acid in postmenopausal women with low bone mineral density. NEJM. 
2002;346(9):653–61. 
Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by 
epidemiology. Bone 1995 Nov;17(5 Suppl):505S-11S. 
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M,  
Landesberg R, Laslop A, Wollenhaupt M, Papa- poulos S, Sezer O, Sprafka M, Reginster 
JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008: 
42: 841– 847. 
 
Siddiqi, A, Payne, AG, Zafar, S. Bisphosphonate-induced osteonecrosis of the jaw: a medical 
enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Sep;108(3):e1-8. 
Statz TA, Guthmiller JM, Humbert LA, Johnson GK. Intravenous bisphosphonate-associated 
osteonecrosis of the jaw. J Periodontol. 2007;78:2203-8. 
Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment 
of osteoporosis. Drug Saf. 2007;30(9):755–763. 
 24 
US Department of Commerce. Hip fracture outcomes in people aged fifty and over: mortality, 
service use, expenditures, and long-term functional impairment (Office of Technology 
Assessment, Congress of the United States, Washington, DC, 1993).  
Walter C, Al-Nawas B, Grotz KA, et al: Prevalence and risk factors of bisphosphonate- 
associated osteonecrosis of the jaw in prostate cancer patients with advanced disease 
treated with zoledronate. Eur Urol 54:1066, 2008 
 
Watts NB, Diab, DL. Long-Term Use of Bisphosphonates in Osteoporosis. J Clin Endocrinol  
Metab 2010; 95: 1555-65. 
 
“WHO Scientific Group on the Asessment of Osteoporosis at Primary Health Care Level: 
Summary Meeting Report.” World Health Organization. 2004. 
 
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and  
osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.  
 
Woodis, C.B. Once-Yearly Administred Intravenous Zoledronic Acid for Postmenopausal  
Osteoporosis. The Annals of Pharmacotherapy 2008; 42: 1085-89.  
